It was the first B-Raf inhibitor to reach clinical trials and, later, approved for renal cancer treatment [71], but failed to show antitumor activity in advanced melanoma when administered as single agent [72] or in combination with other therapeutic drugs [73]. The gene discussed is BRAF; the disease is melanoma.